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A B S T R A C T
Extracellular matrix (ECM)-derived matrices such as Matrigel are used to culture numerous cell types in vitro as
they recapitulate ECM properties that support cell growth, organisation, migration and differentiation. These
ECM-derived matrices contain various growth factors which make them highly bioactive. However, they suffer
lot-to-lot variability, undefined composition and lack of controlled physical properties. There is a need to de-
velop rationally designed biomaterials that can also recapitulate ECM roles. Here, we report the development of
fibronectin (FN)-based 3D hydrogels of controlled stiffness and degradability that incorporate full-length FN to
enable solid-phase presentation of growth factors in a physiological manner. We demonstrate, in vitro and in
vivo, the effect of incorporating vascular endothelial growth factor (VEGF) and bone morphogenetic protein 2
(BMP2) in these hydrogels to enhance angiogenesis and bone regeneration, respectively. These hydrogels re-
present a step-change in the design of well-defined, reproducible, synthetic microenvironments for 3D cell
culture that incorporate growth factors to achieve functional effects.
1. Introduction
In 3D culture, ECM-derived matrices, such as Matrigel, are currently
widely used and support the growth and function of a wide variety of
cell types in vitro, including the formation of organoids, cancer studies
and cell engineering [1–4]. However, Matrigel is an undefined mixture
of ECM proteins and growth factors (GFs) obtained from Engelbreth-
Holm-Swarm mouse sarcoma cells [5]. Matrigel composition is un-
defined, lacking control of mechanical properties and subjected to lot-
to-lot variability. Given this, there is a pressing need to design bioma-
terials that can fulfil the roles of the ECM. However, biomaterials that
have similar stiffness of the target tissue, degradability and that can
present adhesion motifs and GFs with enhanced potency compared to
soluble GFs, have yet to be identified. It is for this reason that Matrigel
is widely used – as it contains proteins and GFs that provide biological
activity not yet achieved by synthetic systems.
GFs are signalling molecules that play essential roles in tissue de-
velopment and organogenesis. GFs drive cell differentiation and sti-
mulate cell migration and proliferation [6]. Given these roles, GFs have
potential clinical utility, particularly in regenerative medicine [7,8].
Despite this, the potential of GFs has yet to be fully realised in medicine,
partly due to their short half-life and rapid clearance in vivo [9,10]. The
ECM acts as a reservoir that binds GFs and coordinates their availability
for cell interactions [11]. For example, the glycosaminoglycan heparin,
has been incorporated into hydrogels to sequester GFs for tissue-en-
gineering applications [12]. Other proteins, such as fibrinogen, tenascin
C or fibronectin (FN) are also known to bind GFs [13–15]. In particular,
FN is an ECM protein widely used to study cell response, e.g. in me-
chanotransduction studies. Classically, FN has been adsorbed onto a
wide range of surfaces [16,17] including synthetic hydrogels such as
polyacrylamide (PAAm) [18] or poly(ethylene) glycol (PEG) [19]. De-
pending on the properties of the surface, adsorption leads to different
conformations, promoting better adhesion properties on hydrophilic
surfaces [20], promoting unfolding [21], fibrillogenesis [22] or dif-
ferent binding to several integrins [23]. FN promiscuously binds GFs,
including therapeutically relevant GFs, such as bone morphogenetic
protein 2 (BMP2, which drives bone formation) [24] and vascular en-
dothelial GF (VEGF, which stimulates angiogenesis) [15]. Importantly,
FN presents the GF-binding site (FNIII12-14) next to the integrin-binding
site (FNIII9-10). This can trigger the simultaneous binding of integrins
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and GF receptors leading to synergistic integrin/GF receptor signalling,
which enhances the effect of GFs on stem cell differentiation and tissue
repair and regeneration [13,25–28].
Material-based strategies have been developed to control GF se-
questration and release, in order to reduce their dosage and to control
their local action [11,29–33] including materials that exploit this sy-
nergistic integrin/GF interaction [34]. Such approaches include the use
of cell-mediated FN fibrillogenesis [35,36], which lacks substantial 3D
structure, or the use of materials that promote FN assembly [37]. On
the latter for example, poly(ethyl acrylate) (PEA) is a polymer that
causes FN to spontaneously unfold and assemble into nanonetworks,
exposing the FNIII9-10 and FNIII12-14 binding sites to cells to enable the
delivery of ultra-low doses of GFs [37–39]. FN assembled on PEA has
been used to successfully present BMP2 in a murine non-healing (cri-
tical-size) bone defect model [40] and in a veterinary case of a dog with
a non-union humeral fracture [39]. This PEA polymer can be used as a
coating for other scaffold materials to target the efficient presentation
of GFs by altering FN's conformation [39].
In 3D, fibrin hydrogels have been functionalised with FN fragments
that contain both the cell adhesion site (FNIII9-10) and the GF binding
site (FNIII12-14) [25]. These hydrogels, loaded with VEGF, promote
wound healing in diabetic mice and, loaded with BMP2, bone re-
generation in a rat non-healing bone defect model [25]. Fibrin hydro-
gels are formed by fibrinogen clotting and so fibrinogen has been in-
corporated in PEG hydrogels to deliver BMP2 [41]. Critically, FN, like
fibrinogen, is an abundant soluble protein in plasma. However, FN is
also present in the insoluble part of the ECM. In this context, the ability
of FN to bind GFs helps the ECM to regulate their bioavailability during
both homeostasis and tissue repair. Full-length FN presents many other
binding sites apart from the cell adhesion domain and the growth factor
binding sites, which are physiologically relevant. For instance, FN
contains two binding sites (FNI1-5 and FNIII12-14) for proteoglycans,
such as syndecan-2 and -4, that trigger focal adhesion assembly via
protein kinase C alpha (PKCα) and focal adhesion kinase (FAK) [42,43].
Also, the variable region of FN contains the Leu-Asp-Val (LDV) and the
Arg-Glu-Asp-Val (REDV) sequences that bind α4β1 and α4β7 integrins
(non RGD-binding integrins) [44,45]. FN also contains FN-binding sites
that are essential for FN fibrillogenesis (FNI1-5, FNIII1-2, FNIII7, FNIII10
and FNIII12-15), and contribute to vascular morphogenesis [46,47]. FN
also has binding sites for collagen and fibrin, among other molecules,
demonstrating the versatile role of FN within the ECM [48–50].
Therefore, the use of full-length FN in synthetic hydrogels is expected to
be advantageous as it recapitulates better than FN fragments the rich
biological activity of FN within the ECM.
The ability to mimic the role of the ECM in GF presentation is key to
developing effective materials-based approaches for 3D culture and
regenerative medicine. The physiological, solid-state presentation of
GFs is also required as their soluble delivery has significant limitations.
For example, clinically, soluble delivery of supraphysiological doses is
required due to the short half-life of unbound GFs and to their clearance
from the site. BMP2 represents an instructive example of the issues that
can arise with traditional GF administration. The use of recombinant
human (rh)BMP2 was approved by the Food and Drug Administration
(FDA) in 2002 and has since then revolutionised the bone graft sub-
stitute market [51,52]. The concentration of BMP2 approved by the
FDA for human use is 1.5 mg mL−1. This high dose has led to increased
incidence of adverse effects, including inflammation, ectopic bone and
tumour formation, wound and urogenital complications [53].
To provide an alternative to natural ECM-derived matrices and to
overcome some of the limitations of synthetic ones such as poor cell
attachment, lack of cell-mediated degradability or absence of solid
phase presentation of GFs [54,55], we report here the development of
synthetic 3D hydrogels that incorporate full-length FN. As a proof of
concept, we demonstrate two examples of important applications in cell
and tissue engineering: vascularisation studies in vitro and bone re-
generation in vivo. Bone is the second most-transplanted tissue after
blood [56]. With bone autografts in short supply and with allografts
being poorly bioactive [57,58], there is still a need for materials that
can improve bone growth [59,60]. Angiogenesis is also of paramount
importance to the health and survival of new or regenerating tissue
[61]. In fact, both angiogenesis and osteogenesis are vital processes in
acute fracture healing and bone repair [62]. Our hydrogels contain full
length, human FN, enabling ultra-low dose, solid-phase presentation of
GFs. In particular, we functionalise the FN protein with PEG-maleimide
(i.e. PEGylation of full-length FN) in order to covalently crosslink the
protein to the synthetic hydrogel network. In this case, the hybrid
polymer-FN network consists of 4-arm-PEG-maleimide crosslinked with
PEG-dithiol and thiolated, protease-degradable peptides. We demon-
strate that the physical properties of this hydrogel can be tuned to re-
capitulate the properties of native ECM. Using BMP2 and VEGF, we
demonstrate the ability of this hydrogel system to recruit and retain GFs
in vitro, thereby providing a novel 3D, functional environment with the
potential to replace Matrigel, and to promote bone regeneration and
vascularisation in vivo.
2. Materials and methods
2.1. Fibronectin PEGylation
Fibronectin (FN, YoProteins, 3 mg mL−1) was PEGylated by mod-
ifying a previously published procedure [63]. FN was denatured in
denaturing buffer (denaturing buffer: 5 mM Tris(2-carboxyethyl)phos-
phine hydrochloride (TCEP, pH 7, Sigma) and 8 M urea (Acros Organics,
99.5%) in phosphate buffer saline (PBS, Gibco, pH 7.4)) for 15 min at
room temperature (RT). Then, 4-arm-PEG-Maleimide (PEGMAL,
20 kDa, LaysanBio) was incubated for 30 min at RT at a molar ratio
FN:PEGMAL 1:4. After PEGylation, remaining non-reacted cysteine re-
sidues were blocked by alkylation using 14 mM iodoacetamide (Sigma)
in PBS at pH 8 for 2 h. The product of the reaction was dialysed using
(Mini-A-Lyzer, MWCO 10 KDa, ThermoFisher) against PBS for 1 h at
RT. The protein solution was then precipitated using cold ethanol.
Briefly, nine volumes of cold absolute ethanol were added to the protein
solution and mixed using a vortex mixer. The mixture was then in-
cubated at −20 °C overnight and centrifuged at 15,000 g and 4 °C for
15 min. The supernatant was discarded, and the protein pellet was
further washed with 90% cold ethanol and centrifuged again at
15,000 g and 4 °C for 5 min. Pellets were dried and solubilised using
8 M urea at a final protein concentration of 2.5 mg mL−1. Once the
protein was dissolved, the solution was dialysed against PBS for 1 h and
stored in the freezer or immediately used.
2.2. Hydrogel formation
PEG hydrogels were formed using Michael-type addition reaction
under physiological pH and temperature following a previously pub-
lished protocol [31]. Briefly, a final concentration of 1 mg mL−1 of
PEGylated FN was added to different amounts of PEGMAL (3 wt%, 5 wt
% or 10 wt%). The thiolated crosslinker was added always at the end, at
a molar ratio 1:1 maleimide:thiol to ensure full crosslinking. The
crosslinkers used were either PEG-dithiol (PEGSH, 2 kDa, Creative
PEGWorks) or mixtures of PEGSH and protease-degradable peptide,
flanked by two cysteine residues (VPM peptide, GCRDVPMSMRGGD-
RCG, purity 96.9%, Mw 1696.96 Da, GenScript). Cells and/or soluble
molecules, such as GFs, were always mixed with the protein and
PEGMAL before addition of the crosslinker. Once the crosslinker was
added, samples were incubated for 30 min at 37 °C to allow gelation.
PEG-only hydrogels were produced as well without the addition of the
PEGylated FN. The nomenclature used in this manuscript is: x% (FN)
PEG yVPM, x being the percentage of PEGMAL used and y the fraction
of degradable crosslinker added. When not indicated, hydrogels were
5% FNPEG 0.5VPM.
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2.3. Fibronectin immunostaining
Hydrogels (3, 5 and 10 wt% FNPEG 0VPM or PEG 0VPM only as a
control) were embedded in optimal cutting temperature compound
(O.C.T compound, VWR) and flash frozen by immersion in liquid ni-
trogen to preserve the structure of the gel. Samples were stored at
−80 °C until use. A cryostat (Leica, −20 °C) was used to cut the
samples, and sections 100 μm in thickness were prepared on treated
microscope slides (Superfrost™ Plus, ThermoFisher).
FN was detected via immunofluorescence in hydrogel cryosections.
Sections were blocked with blocking buffer (1% Bovine Serum
Albumin, BSA, Sigma) for 30 min at RT. Then, primary antibody rabbit
polyclonal-anti-FN (Sigma, 1:400) was added and incubated for 1 h at
RT. Samples were washed three times using washing buffer (0.5%
Tween 20 (Sigma) in PBS). Then, secondary antibody goat-anti-rabbit-
Cy3 (Jackson ImmunoResearch, 1:200) was incubated for 1 h at RT and
protected from light. Samples were washed three times using washing
buffer and were mounted with VECTASHIELD mounting media without
DAPI (Vector Laboratories). Images were taken with a ZEISS
AxioObserver Z.1 at different magnifications.
2.4. Fibronectin release
FN release at 24 h was measured as a way to demonstrate that
PEGylated FN was covalently crosslinked to the PEG network. If FN is
covalently crosslinked there should not be any FN release, whereas if
we add native FN into the hydrogel system, as it is not crosslinked, by
diffusion FN should be released. To do so, hydrogels (either 5% FNPEG
0VPM, 5% PEG 0VPM or 5% PEG 0VPM hydrogels with native FN
entrapped (PEG + FN)) were immersed for 24 h in PBS to assess the
release of FN. Native FN was mixed in solution with the PEGMAL
polymer prior to the addition of the crosslinker in order to entrap FN
within the PEG hydrogels (PEG + FN condition). Solutions from su-
pernatants were collected and quantified using bicinchoninic acid col-
orimetric assay (MicroBCA assay kit, ThermoFisher Scientific), fol-
lowing the manufacturer's instructions. Briefly, BSA and FN standards
together with samples were loaded onto a 96-well microplate and were
mixed with the working reagent. Then, the microplate was sealed and
incubated for 2 h at 37 °C. After incubation, the microplate was let to
cool down for 20 min at RT, protected from light. The absorbance at
562 nm was measured using a plate reader (BIOTEK). Conditions were
prepared in triplicate and samples were measured in triplicate.
2.5. Water absorption
Hydrogels were formed, weighed (m0) and immersed in milliQ
water for up to a week using filtered tubes (Corning® Costar® Spin-X®
centrifuge tube filters, cellulose acetate membrane, pore size 0.45 μm).
After 24 h, samples were centrifuged at 6500 rpm for 5 min to remove
the supernatant from the basket so that only the hydrogel sample re-
mained in the basket holder. Then, sample and basket were weighed,
and the mass of the empty basket was subtracted. The amount of water
absorbed was calculated as follows:
=
−
∗Water Sorption m m
m
(%) 100t 0
0 (1)
Where mt is the weight of the hydrogel at a certain time and m0 the
weight of the hydrogel after formation.
2.6. Mechanical properties
Nanoindentation was assessed using atomic force microscopy in
force spectroscopy mode (AFM/FS, Nanowizard-3, JPK). Cantilevers
(Arrow-TL1-50, spring constant ~ 0.03 N/m, Nano World innovative
technologies) were functionalised manually with silicon oxide mi-
crobeads (20 mg mL−1, 20 μm diameter, monodisperse, Corpuscular
Inc.). The actual stiffness of the cantilever was estimated using the
thermal calibration method. Samples tested were 100 μm cryosections
fully swollen in milliQ water. Cryosections were thawed for 5 min at
RT. A hydrophobic marker (PAP pen, Vectorlabs) was used to surround
the sample and milliQ water was added for 15 min. After swelling,
samples were rinsed twice with milliQ water to wash off the remaining
O.C.T of the cryosection. Measurements were carried out in immersion.
Indentation of at least 500 nm were assessed using constant force. The
area of the sample was mapped defining squared areas (2500 μm2, 25
measurements). Five maps per replicate were measured and at least
three replicates per sample were tested, unless otherwise noted. The
analysis (JPK-SPM processing software) was performed using the Hertz
model for a spherical indenter to fit the curves obtained.
2.7. Degradation assays
Hydrogels were formed and swollen overnight in PBS. All samples
were weighed before starting the degradation. Then, samples were
covered with protease solution (collagenase type I, Gibco, 50 U mL−1 in
PBS, 37 °C). At each timepoint, all supernatant was removed by cen-
trifugation at 6500 rpm for 5 min and samples were weighed. To
continue the experiment, fresh protease solution was added. The de-
gradation rate was calculated as follows:
=
−
∗M M M
M
(%) 100loss i t
i (2)
Where Mloss is the percentage of mass lost during degradation, Mi the
mass after swelling in milliQ water (initial mass), and Mt, the mass at
the different timepoints after the addition of the protease solution.
2.8. Growth factor labelling
In order to study GF binding and release, VEGF or BMP2 (carrier
free, R&D Systems) were fluorescently labelled with an amino reactive
dye (DyLight® NHS Ester, Thermo Fisher Scientific) following the
manufacturer's instructions. Briefly, GFs were dialysed (Mini-A-Lyzer,
COMW 10 kDa, ThermoFisher) against 0.05 M Sodium borate buffer at
pH 8.5 for 2 h at RT. Then, the appropriate amount of dye was added
(as calculated by the manufacturer's guidelines) to the GF solution. The
dye and the GF were let to react for 1 h at RT, protected from light.
Then, the non-reacted dye was removed by dialysis against PBS for 3 h.
The labelled VEGF was aliquoted and stored at −20 °C until use.
Fluorescently labelled VEGF or BMP2 were named VEGF-488 or BMP2-
488, respectively, in the main text.
2.9. Growth factor release
Hydrogels were prepared, as described in hydrogel formation sec-
tion above, that incorporate VEGF-488 or BMP2-488. The final con-
centration of labelled GF loaded was 10 μg mL−1 (unless otherwise
noticed). Then, samples were immersed in PBS and incubated at 37 °C
protected from light. At each timepoint, all the PBS solution was taken
and used to measure the fluorescence (Ex/Em 493/518 nm) using a
plate reader (BIOTEK). Fresh PBS was added after each timepoint. A
standard curve using VEGF-488 or BMP2-488 was prepared and mea-
sured together with the samples. An empty condition (not loaded with
GF) was used as control. All conditions were prepared in triplicate, and
each sample was measured three times. The cumulative release (%) was
calculated as follows:
=GF m m(%) 100 /released GFs GFi (3)
Where GFreleased is the percentage of VEGF-488 or BMP2-488 released
from hydrogels, mGFs is the amount of VEGF-488 or BMP2-488 mea-
sured in the supernatant and mGFi is the amount of VEGF-488 or BMP2-
488 initially loaded.
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2.10. VEGF uptake
Hydrogels were immersed in 10 mM L-cysteine solution for 2 h to
ensure that all the maleimide groups from the hydrogels were reacted.
After that, samples were washed three times in PBS and immersed in
VEGF-488 solutions of different concentrations (5, 10 and 15 μg mL−1).
Once immersed, samples were incubated for 20 h at 37 °C while pro-
tected from light. The supernatant was then taken and read using a
plate reader (Ex/Em 493/518 nm). All conditions were prepared in
quadruplicate and all samples were measured twice. The initial solu-
tions were also measured and used as standard curve to be able to
correlate fluorescence intensity with VEGF-488 concentration. The
fluorescence intensity of hydrogels immersed in PBS (without VEGF-
488) was measured to normalise the data. The percentage of VEGF-488
absorbed was calculated as follows:
= −m m mVEGF absorbed VEGFi VEGFs (4)
Where mVEGF absorbed is the final mass of VEGF-488 retained in the
hydrogels, mVEGFi is the initial total mass of VEGF-488 added to the
samples in solution, and mVEGFs is the total mass of VEGF-488 measured
in the supernatant after incubation. Once the amount of VEGF-488
retained in the samples was calculated, the percentage of VEGF-488
absorbed was calculated as follows:
= −VEGF VEGF (%) 100  (%)absorbed soluble (5)
Where VEGFabsorbed is the percentage of VEGF retained in the hydrogel
and VEGFsoluble is the percentage of VEGF measured from the super-
natants after the incubation of VEGF with the hydrogel.
2.11. Cell culture
Human umbilical vein endothelial cells (HUVECs) (Caltag
Medsystems, passage 1–5) were used for viability and angiogenesis/
vascularisation in vitro assays. HUVECs were grown in growth media
(large vessel endothelial cell (LVEC) medium, Caltag Medsystems).
Human dermal fibroblasts (HDFs) (Caltag Medsystems, passage 1–6)
were used for angiogenesis studies. Both cell types were grown in
Dulbecco's modified Eagle's medium (DMEM, Gibco) high glucose
without pyruvate and 10% fetal bovine serum (FBS, Gibco) until
seeding. Once seeded, LVEC media was used. All media used were
supplemented with 1% penicillin/streptomycin (Gibco).
2.12. Cell viability
Cytocompatibility of hydrogels was tested using the Live/Dead
assay (ThermoFisher), according to the manufacturer's instructions.
Briefly, HUVECs cells were encapsulated at 106 cells·mL−1 to allow
single-cell analysis and were incubated within the hydrogels at different
timepoints. For each timepoint, cells were stained with 2 μM Calcein-
AM and NucBlue and incubated for 15 min. Samples were washed twice
before imaging with a confocal microscope (ZEISS CLSM 880) at 10×
magnification. Images were quantified using ImageJ 1.51v (National
Institutes of Health, US).
= ∗( )Viability live cells N(%) 100total (6)
Being Ntotal the total number of cells in that field of view
(alive + dead cells).
2.13. Angiogenesis assays
Angiogenic sprouting was assessed using bead microcarriers [64].
Briefly, HUVECs were mixed with dextran-coated Cytodex 3 micro-
carriers (Sigma) at a final concentration of 400 cells per bead in 1 mL of
growth medium. Cells and beads were mixed gently every 20 min for
4 h at 37 °C. Then, cell-coated beads were transferred to a flask with
growth medium and incubated overnight (37 °C and 5% CO2). Before
encapsulation, cell-coated beads were washed three times with growth
medium. Finally, cell-coated beads were loaded into hydrogels at a final
concentration of 400 beads·mL−1. Once the hydrogels were prepared,
twenty thousand human dermal fibroblasts were seeded on top fol-
lowing protocol described by others [64,65]. When human dermal fi-
broblasts were not added to the experiment, sprouting was not observed
regardless of the presence of VEGF. Conversely, when only fibroblast
are added to the hydrogels (but no VEGF) sprouting does not happen
either.
Growth media supplemented with different concentrations of VEGF
(0, 50, 500 ng mL−1, R&D Systems) was changed every other day. The
assay was monitored every day for four days via brightfield microscopy.
Samples were fixed using 4% para-formaldehyde for 30 min at RT and
stained for actin (AlexaFluor-488 Phalloidin dilution 1:300) and for the
nucleus (NucBlue, LifeTechnologies) for 1 h. Samples were washed
three times with 0.5% Tween 20 in PBS and mounted onto glass bottom
petri dishes using VECTASHIELD mounting medium (VectorLabs).
Samples were imaged using a ZEISS Axio Observer Z1 and were pre-
pared in triplicate. Actin images were used for quantification. They
were converted into 8-bit greyscale images using ImageJ. After that, the
“Find connected regions” plugin of ImageJ was used with the following
parameters: find all regions, do not allow diagonal connections, count
only regions with intensity values over 50 (to reduce noise), count only
regions with a minimum of 100 connected pixels.
2.14. Vascularisation assays
For vascularisation studies, HUVECs were encapsulated
(5·106 cells·mL−1) in situ within hydrogels loaded with 200 pmol mL−1
VEGF-165 (R&D Systems) or within non-loaded hydrogels (without GF).
Samples at days one, two and three were fixed with 4% para-for-
maldehyde for 30 min at RT and stained for actin and the nucleus.
Samples were imaged using confocal microscopy (ZEISS LSM 880) at
10× magnification. Stacks obtained from confocal imaging were ana-
lysed using ImageJ 1.51v. Briefly, actin cytoskeleton stacks were
opened and segmented using the trainable Weka segmentation 3D
plugin. Once the stacks were converted to 8-bit segmented stacks, the
segmented objects were quantified using the “3D objects counter” tool
with the following parameters: volume (V, μm3), number of voxels/
object, surface (S, μm2), number of voxels/surface and centroids. Prior
to the quantification, a size exclusion filter was applied, so objects
smaller than 500 voxels were not counted (to avoid quantification of
segmented background noise). The sphericity (Ψ) of the objects was
calculated as follows:
=
π V
S
Ψ (6 )
1
3 2/3
(7)
2.15. Chick chorioallantoic membrane assay
Fertilised chick eggs were received at day seven post-fertilisation
(E7). Eggs were kept in an incubator (37.5 °C, 50–60% relative hu-
midity). To perform the chorioallantoic membrane (CAM) assay, eggs
were candled to detect and mark the air sac of the chick embryo, and
the egg shell was then cut on top of the air sac to expose the CAM. Once
the membrane was exposed, each sample was laid carefully on top of
the membrane. Samples tested were: 5% PEG 0.5VPM, 5%PEG 0.5VPM
with 2.5 μg mL−1 VEGF165, 5% FNPEG 0.5VPM, 5% FNPEG 0.5VPM
with 2.5 μg mL−1 VEGF165 and an empty condition, where the CAMs
were exposed but no material was placed on top. After that, the exposed
area of the egg with the sample was sealed and labelled. All eggs were
incubated for four days (E12), when the membranes were imaged using
a stereomicroscope (Leica MZ APO) using X8 and X16 magnification.
Six replicates per condition were used; two pictures per replicate at
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each magnification used were taken. For the quantification, images at
X16 magnification were used and the images were anonymised. The
green channel of the RGB picture was chosen for the segmentation as it
was the one with the best contrast to detect the capillaries.
Segmentation was assessed manually, tracing a black line on top of each
capillary. The result of the segmentation was used to quantify the
number of branches, the number of junctions, and the number of triple
points per image via the skeletonize tool on ImageJ.
2.16. Murine non-healing bone defect model
This experiment was conducted under the Animals (Scientific
Procedures) ACT 1986 (ASPel project license n° 70/8638). All murine
experiments were conducted under the Animals (Scientific Procedures)
ACT 1986 (ASPel project license n° 70/8638) and all the research
performed, complied with ethical regulations approved by the
University of Glasgow's ethical committee.
2.16.1. Implant preparation
Polyimide implant tubes with lateral holes were used as sleeves to
be filled with the hydrogel samples (final volume used 3 μL). The im-
plant tubes were immersed in ethanol and sonicated for 10 min. After
sonication, implant tubes were rinsed twice with ethanol and then
autoclaved. FN hydrogels (5 wt%, FNPEG 0.5VPM) were loaded with
BMP2 (R&D Systems) at a final concentration of 0, 5 or 75 μg mL−1
(FNPEG-, FNPEG + or FNPEG++, respectively). The implants were
prepared the day before surgery under sterile laminar flow hood and
were kept in PBS and 37 °C, 5% CO2 until use.
2.16.2. Bone radial segmental defect surgery
C57BL/6 male mice (8 weeks old, Charles River, n = 5 mice/con-
dition) were anaesthetised using isoflurane gas. Under anaesthesia,
mice were provided with a dose of buprenorphine and carprofen for
pain relief. An incision on the skin was carried out along the forearm
and the radius was exposed using a periosteal elevator. The centre of
the radius was revealed in order to introduce a 2.5 mm wound in the
bone, using a custom-made parallel double-bladed bone cutter. The
ulna was left intact. The implant was then placed into the introduced
bone defect, abutting its proximal and distal ends. Finally, the wound
was closed with a degradable suture. Mice were monitored during the
experiment for signs of distress, movement, and weight loss.
2.16.3. Analysis of bone growth
Eight weeks after surgery, bone samples were explanted and fixed in
4% para-formaldehyde and immersed in 70% ethanol. Bone samples
were analysed using microcomputer tomography (μCT, Bruker Skyscan
Micro X-ray CT), and then decalcified using Krajian solution (citric acid,
formic acid) for 3 d, until soft and pliable. They were then paraffin
embedded for sectioning. Quantification of the bone volume was per-
formed using the CTAn software (Bruker). In order to ensure that only
new bone formation was measured, the volume of interest (VOI) was
selected to evaluate a central 2.0 mm length of the 2.5 mm total defect
size. For histological analysis, sections (of 7 μm thickness) were stained
for haematoxylin-Safranin O-Fast Green. Briefly, sections were depar-
affinised and rehydrated in water. Then, Mayer's haematoxylin staining
was performed for 8 min and Scott's solution was used for 1 min to blue
up the nuclear staining. After that, samples were rinsed in 1% acid
alcohol and water. Then, 0.5% fast green solution for 30 s was used to
stain collagen and sections were rinsed in 1% acetic acid for 3 s. Finally,
0.1% safranin O solution was used for 5 min to counterstain the carti-
lage and sections were washed in 70%, 95% and absolute ethanol for
1 min each. Sections were cleared twice with Histo-Clear for 5 min and
mounted with DPX mounting media. Sections were then imaged with an
EVOS FL microscope (ThermoFisher) at 20× magnification. Whole
mounts were stitched together using the Image Composite Editor soft-
ware.
2.17. Statistical analysis
The statistical analysis was performed using GraphPad Prism 6.01
software. All in vitro experiments were carried out in triplicate unless
otherwise noticed. All graphs represent mean ± standard deviation
(SD) unless otherwise noted. The goodness of fit of all datasets was
assessed via D'Agostino-Pearson Normality test. When comparing three
or more groups: normal distributed populations were analysed via
analysis of variance test (ANOVA test) performing a Tukey's post hoc
test to correct for multiple comparisons; when populations were not
normally distributed, a Kruskal-Wallis test was used with a Dunn's post
hoc test to correct for multiple comparisons. When comparing only two
groups, parametric (normal distributed population, t-test) or non-
parametric (Mann-Whitney test) tests were performed. Differences
among groups are stated as follows: for p-values< 0.05 (*), when p-
values< 0.01 (**), for p-values < 0.005 (***), for p-values < 0.001
(****), when differences between groups are not statistically significant
(n.s).
3. Results
3.1. Fabrication and characterisation of full-length FN hydrogels
FN was covalently incorporated into a poly(ethylene) glycol (PEG)
network via Michael-type addition reaction, where a 4-arm-PEG-mal-
eimide spontaneously reacts with a thiolated crosslinker at physiolo-
gical pH (Fig. 1a and b, Fig. S1). Maleimide groups were chosen to
fabricate the hydrogels because they have higher affinity towards thiol
groups and confer shorter gelation times at physiological pH relative to
hydrogels fabricated using acrylate groups as demonstrated by Phelps
and colleagues [66]. Moreover, Michael-type addition has been pre-
viously used to form biologically active and cytocompatible hydrogels
[67,68].
Prior to hydrogel formation, the disulfide bonds that hold the FN
dimers together were reduced to obtain two FN monomers. FN mono-
mers were then PEGylated via a Michael-type addition reaction by
functionalisation of the FN cysteine residues with a molar ratio FN
monomer to 4-arm-PEG-maleimide of 1–4 (Fig. S2). This ratio was
chosen after preliminary optimisation and to use the minimum amount
possible of PEG molecules for PEGylation. As PEGylation is a stochastic
process we decided to use Michael-type addition to selectively target
cysteine residues on FN. We tested the biological activity of the PE-
Gylated FN (Fig. S3). We used enzyme-linked immunosorbent assay
(ELISA) with three monoclonal antibodies targeting different domains
of FN (Figs. S3a and b) and found it had similar availability of the cell
adhesion-binding site and the GF-binding domain (Figs. S3c and d) to
native FN. As expected, differences between native and PEGylated FN
were found mainly at the collagen binding site, which was less available
in the PEGylated version (Fig. S3e) relative to the native form. This is
due to PEG molecules principally binding to the FN type I and II re-
petitions, which are the domains that contain cysteine residues
(Fig. 1a). We did not observe differences between the native and PE-
Gylated FN forms when assessing adhesion and focal adhesion forma-
tion in C2C12 cells, demonstrating that cells can fully interact with the
protein after PEGylation (Fig. S3f-m). These findings agree with pre-
vious work reporting that PEGylated FN retains biological activity in
terms of cell adhesion and FN fibril assembly, together with some
proteolytic stability [69,70]. It is also noteworthy that full-length pro-
teins are reported to retain high biological activity after the PEGylation
process when incorporated into hydrogel systems [63,71,72].
We then assessed the homogeneous distribution of FN within the
hydrogel network via immunostaining (Fig. 1c). Hydrogels without FN
did not show any staining (Fig. S4a). We also tested the efficiency of
binding between FN and PEG by studying the release of FN from the
hydrogels after 24 h (Fig. 1d) and the presence of FN in the supernatant
after release via electrophoresis and Coomassie blue staining (Fig. S4b).
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Hydrogels into which PEGylated FN had incorporated (i.e., covalently
bound FN) did not release FN (FNPEG 0VPM, Fig. 1d, Fig. S4b),
whereas PEG hydrogels into which native FN was encapsulated (i.e.,
simply trapped, non-covalently bound FN) released approximately 10%
of the initial FN added after 24 h (PEG + FN condition, Fig. 1d).
Using PEG as a hydrogel network allows the physicochemical
properties of the system to be controlled [73–75]. Increasing the
amount of PEG in the system (from 3 to 10 wt%) increases water ab-
sorption in the hydrogels (Fig. 1e), increases Young's modulus (Fig. 1f),
both independently of FN, the concentration of which was kept constant
in the hydrogels at 1 mg mL−1. As the Young's modulus increases, the
mesh size of the hydrogel decreases (Fig. S5). The average Young's
modulus (± SD) observed for 3% FNPEG 0VPM hydrogels was
2.6 ± 1.7 kPa and for 3% PEG 0VPM 2.6 ± 1.5 kPa. For 5 wt %
hydrogels, the mean Young's modulus obtained was 5.9 ± 3.5 kPa for
5% FNPEG 0VPM and 4.8 ± 2.7 kPa for 5% PEG 0VPM hydrogels.
Hydrogels of 10 wt % showed an average Young's modulus of
8.8 ± 5.3 kPa for 10% FNPEG 0VPM hydrogels and 12.5 ± 4.9 kPa
for 10% PEG 0VPM hydrogels. These results agree with previously
published results on standard PEG hydrogels, where an increase in the
PEG percentage resulted in an increase in the Young's modulus
[63,73,74,76]. PEG hydrogels can also be engineered to be cell-de-
gradable [12]. To demonstrate controlled levels of degradation, we
incorporated a protease degradable crosslinker (VPM peptide, Fig. S1)
in combination with thiolated PEG. The degradation rate of hydrogels
upon collagenase type I treatment increased with increasing amounts of
VPM crosslinker, both for FN-containing hydrogels, FNPEG, and PEG
hydrogels without FN (Fig. 1g and Fig. S4d). The addition of increasing
ratios of the VPM peptide did not affect either the water sorption ability
of the hydrogels (Fig. S4c) nor their mechanical properties up to ratio
0.3VPM (Fig. 1h). We note that ratio 0.5VPM increased the mechanical
properties of the hydrogel, from 5.9 ± 3.5 kPa of 0VPM and
6.2 ± 3.7 kPa of 0.3VPM to 9.3 ± 4.9 kPa of 0.5VPM (mean ± SD).
Together, these data demonstrate that full-length and functional FN
can be incorporated into a synthetic hydrogel system that has con-
trolled stiffness and degradation rates.
3.2. Full-length FN hydrogels sequester growth factors
As discussed, FN can promiscuously bind GFs, such as VEGF,
through the heparin II-binding domain (FNIII12-14) as long as this do-
main is available for interaction [15,38,40]. We demonstrate the ability
Fig. 1. FN hydrogel formation and characterisation. (a) Schematic of the modular composition of FN (upper structure, domains I, II and III are depicted in blue, red
and yellow, respectively, and cysteine residues are marked as *), and structure of the 4-arm-PEG-maleimide. (b) A schematic of the hydrogel formation protocol,
where FN is depicted in orange. (c) Immunofluorescence of FN (in red) in cryosections of 3, 5 and 10 wt % FNPEG 0VPM hydrogels (from left to right, scale bar:
100 μm). (d) Fraction of FN released after 24 h (mean ± SD, n = 3) from hydrogels into which PEGylated FN had incorporated (FNPEG 0VPM, covalently bound
FN) or FN had encapsulated (PEG + FN, non-covalently bound FN, PEG 0VPM hydrogels). (e) Water absorption at 24 h of 3, 5 and 10 wt% PEG 0VPM only and
FNPEG 0VPM hydrogels (mean ± SD, n = 4). (f) Elastic modulus measured by AFM nanoindentation of 3, 5 and 10 wt% PEG only and FNPEG 0VPM hydrogels
(mean ± SD, n > 100 curves). (g) Degradation profile of FNPEG with different ratios of degradable crosslinker (0, 0.1, 0.2, 0.3, 0.5VPM) (mean ± SD, n = 3). (h)
FNPEG hydrogels with different ratios of degradable crosslinker (0, 0.3, 0.5VPM) (mean ± SD, n > 100 curves, *p-value<0.05, ANOVA test followed by a Tukey's
post hoc test). FN was covalently incorporated into PEG hydrogels, which could be further tuned to control their stiffness and degradability. (For interpretation of the
references to color in this figure legend, the reader is referred to the Web version of this article.)
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of FN hydrogels to actively sequester GFs, compared to PEG only hy-
drogels (Fig. 2). VEGF was fluorescently labelled to track its release
over time (Fig. 2a). This strategy allowed us to track diffusion of VEGF
up to approximately 0.1 μg/mL, according to our standard curve.
FNPEG hydrogels retain up to 50% of the VEGF that was initially loaded
into the hydrogel, compared to the total release of VEGF from PEG only
hydrogels after 24 h (Fig. 2b and c). The release of VEGF probably
continues at a slower rate because the isoform used (VEGF165) has in-
termediate affinity to the ECM [77]. We note a burst release during the
first 3 h, which is expected in hydrogels. We also note that the presence
of VPM peptide did not affect VEGF's sequestration (Fig. 2d), as ex-
pected, because we did not use proteases in the experiment. This de-
monstrates that FNPEG hydrogels can be engineered to control GF
presentation independently of their degradability.
We also investigated the release of VEGF from Matrigel and PEG-
RGD hydrogels (Fig. S6). PEG-RGD hydrogels were prepared using PEG-
MAL and an equivalent amount of RGD peptide to the amount of FN
used for FNPEG hydrogels. PEG only and PEG-RGD showed similar
release at 72 h, where approximately 75–80% of the VEGF initially
loaded was released. On the contrary, Matrigel showed sequestration of
VEGF, as it only released 65% of the VEGF loaded. Still, FNPEG hy-
drogels were able to sequester more VEGF compared to Matrigel and
thus, also compared to PEG only and PEG-RGD.
The capability of FNPEG hydrogels to sequester VEGF was further
demonstrated in an uptake assay (Fig. 2a). In this assay, hydrogels were
immersed in solutions that contained fluorescently labelled VEGF and
their absorption was then measured (Fig. 2e and f). FN hydrogels ab-
sorbed more VEGF compared to PEG only hydrogels for all concentra-
tions of the initial VEGF solution used (Fig. 2e and f). The increased
uptake of VEGF in the FNPEG hydrogels cannot be explained by simple
passive diffusion of the GF through the PEG network alone, since both
PEG and FNPEG hydrogels absorbed similar amounts of water (Fig. 1e).
This demonstrates, together with results from VEGF release experi-
ments, that FN binds VEGF as it diffuses from the initial solution, and
that VEGF becomes part of the ‘solid phase’ of the hydrogel, and allows
more GF to diffuse until equilibrium is reached. The difference in VEGF
uptake between FNPEG and PEG, as shown in Fig. 2f, for each con-
centration must be from the VEGF that is bound to FN in the hydrogel.
These data show the solid-phase presentation of GFs from crosslinked
FN in a synthetic 3D hydrogel with controlled stiffness and degradation
rate. To further put in context the differences observed in Fig. 2f,
FNPEG hydrogels uptake on average 2 μg of VEGF per mL of hydrogel
more than PEG only gels.
In the subsequent experiments, we used only 5 wt% FNPEG and PEG
gels with a ratio of 0.5 VPM.
3.3. Full-length FN hydrogels promote microvasculature growth
We next assessed whether having VEGF in FN hydrogels promote
endothelial cell activation and microvasculature growth. Human um-
bilical vein endothelial cells (HUVECs) were encapsulated, in situ, in
both PEG only and FNPEG hydrogels, and retained high cell viability
(Fig. 3a), as expected, due to the mild crosslinking chemistry used to
form the hydrogels [78,79]. To investigate endothelial sprouting in 3D,
we seeded HUVECs onto microcarrier beads [64,65]. These micro-
carrier beads are collagen-coated dextran beads hence, HUVECs can
attach to the external coating. These cell-coated beads sustain a semi-
confluent layer of cells, that were afterwards encapsulated within
FNPEG hydrogels or in Matrigel (positive control, Fig. 3b). For this
experiment VEGF was supplemented in the media. Qualitatively,
Fig. 2. FN hydrogels actively bind VEGF. (a) Schematic of the release experiment in which the hydrogel is loaded with 10 μg/mL of fluorescently labelled VEGF. The
hydrogel was then immersed in PBS and the fluorescent intensity of the supernatant tracked through time. Also, schematic of the VEGF uptake assay, in which a
hydrogel was immersed in solutions of 5, 10 and 15 μg/mL of fluorescently labelled VEGF and the fluorescence intensity of the supernatant measured. (b) The
cumulative release of fluorescently labelled VEGF from PEG 0VPM only and FNPEG 0VPM hydrogels, loaded with 10 μg mL−1 VEGF (mean ± SD, n = 6, ***p-
value < 0.001, Kruskal-Wallis and Dunn's post hoc test). (c) Concentrations measured of fluorescently labelled VEGF released from PEG 0VPM only and FNPEG
0VPM (mean ± SD, n = 6). (d) Cumulative release of fluorescently labelled VEGF at 64 h from PEG and FNPEG with different ratios of VPM (0, 0.2, 0.3 and
0.5VPM) (mean ± SD, n = 3 ***p-value< 0.001, ANOVA with a Tukey's post hoc test). (e) Percentage of VEGF absorbed (*p-value < 0.05, Kruskal-Wallis with a
Dunn's post hoc test) and (f) amount of VEGF absorbed by PEG 0VPM only and FNPEG 0VPM hydrogels (*p-value < 0.05, Kruskal-Wallis and Dunn's post hoc test).
FNPEG hydrogels incorporate VEGF that is stably bound to FN in the 3D environment.
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FNPEG hydrogels showed high levels of sprouting, similar to those
observed in Matrigel (Fig. 3b). Quantitatively, the area covered by
connected sprouts was measured using the actin staining. Results from
this quantification showed that both FNPEG and Matrigel supplemented
with VEGF in the media presented, on average, larger interconnected
areas of sprouts. A higher number of very large areas were quantified
for the FNPEG condition and Matrigel (supplemented with VEGF),
which corresponds to images covered by sprouts as can be seen from the
images in Fig. 3b. Comparing FNPEG to Matrigel (both with VEGF)
there are more highly connected areas (> 100,000 pixel2), although
this was not statistically significant. We note that for both FNPEG hy-
drogels and Matrigel sprouting only occurred in the presence of
500 ng mL−1 VEGF. The use of 50 ng mL−1 VEGF resulted in no
sprouting in either FNPEG or Matrigel conditions. Comparing our re-
sults with others [64,65] and although the amount of VEGF needed in
this case was higher (500 ng/mL compared to 1–30 ng/mL [64]), our
system provides a well-defined material (for example compared to fi-
brin clots [64,65]) that requires solely of VEGF in the media to promote
sprouting (compared to the addition of VEGF, basic fibroblast GF, an-
giopoietin-1and transforming growth factor-β used by others [64]).
Next, we investigated whether FNPEG gels promote HUVEC re-
organisation in a 3D context, as happens in Matrigel (Fig. 3c and d). To
do so, we encapsulated HUVECs and VEGF within FNPEG hydrogels, as
well as within Matrigel and PEG controls, and tracked cell morphology
at early timepoints. In this case VEGF was loaded directly into the
hydrogels together with HUVECs. We found that endothelial cells un-
derwent more extensive morphological and structural changes within
the VEGF-containing FNPEG hydrogels, as compared to the cells in the
VEGF-containing Matrigel and PEG only hydrogel (Fig. 3c, d and Fig.
S7). At days 1 and 2 after encapsulation, endothelial cells within the
VEGF-containing FNPEG hydrogels formed multicellular and inter-
connected structures, as demonstrated in the 3D reconstruction images
and volume quantification (Fig. 3d). Endothelial cells did not form
these complexes in PEG only (with or without VEGF), although cells in
VEGF-containing Matrigel did show some multicellular structures,
consisting of 3–4 cells at days 2 and 3. At day 3, the endothelial cell
clusters formed in VEGF-containing FNPEG hydrogels started to dis-
assemble, suggesting that these cellular complexes were not stable.
During vasculogenesis, endothelial cells are highly dynamic and come
together to form primitive capillary structures [80]. However, they
require guidance from other cell types, such as pericytes and smooth
muscle cells, to stabilise the newly formed capillary [81,82]. These
experiments demonstrate that FNPEG hydrogels sequester VEGF and
induce endothelial cells to form the early structures associated with
vascularisation, more extensively than in cells cultured in Matrigel,
even though Matrigel is able to sequester approximately 35% of initial
VEGF loaded as shown by release studies (Fig. S6). This suggests that
PEG-RGD loaded with VEGF would perform as FNPEG without VEGF,
due to its quick release of> 70% of initial VEGF loaded.
After showing that FNPEG hydrogels promote endothelial cell
sprouting in 3D, we tested the system in a more complex environment
using the chick chorioallantoic membrane (CAM) assay (Fig. 4). Hy-
drogels (FNPEG hydrogel and PEG control) loaded with VEGF (and
controls without VEGF) were placed on top of the exposed CAM, and
chick embryos were incubated for four days. For this experiment, where
we wanted to assess whether or not the sequestration of VEGF improved
capillary formation, PEG hydrogels were used as controls and Matrigel
was not included in the experiment.
After incubation, images of the CAM underneath and near the hy-
drogel were taken and quantified. We note that in some cases hydrogels
seemed to have fused with the actual CAM. The results show that in-
creased capillary formation occurred when FNPEG (with or without
VEGF) was present, as can be seen by the number of branches and
junctions counted per field (Fig. 4c and d). CAMs incubated with VEGF-
containing PEG only lacked extensive capillary formation, as seen in the
empty condition (when a CAM was exposed but no material was placed
on top). This is likely to be due to a rapid release of VEGF from PEG
during the first hours, causing VEGF to be lost from the local en-
vironment relatively quickly. This would be in accordance with our
VEGF release studies (Fig. 2b–d), which showed that VEGF is rapidly
released from PEG only hydrogels during the first 24 h. In contrast,
FNPEG hydrogels (with or without VEGF) showed the highest levels of
capillary formation. This is likely to be due to FNPEG hydrogels pro-
viding a more sustainable release of VEGF (as shown in our release
studies, Fig. 2b and c) but also because of the likely sequestration of
natural VEGF present in the developing CAM [83–85], as also demon-
strated in our in vitro VEGF uptake tests (Fig. 2e and f).
3.4. BMP2-loaded FN hydrogels promote bone formation
We used a non-healing (critical size), radial bone defect model in
the adult mouse to demonstrate that FNPEG hydrogels promote bone
formation in vivo when loaded with low concentrations of BMP2
(Fig. 5). In this model, a 2.5 mm defect was introduced into the radial
bone that does not heal spontaneously (Fig. 5d). The ulna was left intact
to provide mechanical stabilisation and to avoid the use of additional
external fixation plates. Hydrogel-filled implant tubes, 4 mm in length
and that contain multiple pores along their sides (Fig. 5b) [39,40,86]
were placed inside the bone defect.
To use this model, we first studied the release of BMP2 from the
hydrogel system in vitro (Fig. 5a and b). We observed that, for an initial
amount of BMP2 of 10 μg/mL, FNPEG hydrogels released approxi-
mately 70% of the BMP2 initially loaded into them in the first 4 h,
whereas PEG only hydrogels (that do not contain FN) released more
than 90% of the BMP2 loaded into them in the same time period
(Fig. 5a). We hypothesised that 30% of BMP2 in FNPEG hydrogels re-
mained bound to FN.
We used two initial concentrations of BMP2 for this experiment: 5
and 75 μg/mL (denoted as FNPEG+ and FNPEG++, respectively).
Implant tubes were filled with FNPEG hydrogels loaded with BMP2 the
day before the experiment (hydrogels without BMP2 were used as a
control, denoted FNPEG-). We tracked the release of BMP2 from FNPEG
hydrogels at 24 h using the two selected initial concentrations of BMP2,
to estimate the amount of BMP2 that remained in the hydrogel prior to
implantation (Fig. 5b). FNPEG hydrogels loaded with 5 μg/mL released
27 ± 11% of BMP2 after 24 h and, FNPEG hydrogels loaded with
75 μg/mL released 88 ± 6% of the initial BMP2 after 24 h (mean ±
SD). Because some of the BMP2 loaded is released during the first hours
Fig. 3. FN hydrogels promote sprouting and microvasculature growth in 3D. (a) Percentage viability of HUVECs after encapsulation in FNPEG 0.5VPM and PEG
0.5VPM only hydrogels. (b) (Top left) Schematic of 3D sprouting assay, in which HUVECs were seeded onto collagen-coated dextran beads and the cell-coated beads
encapsulated in FNPEG 0.5VPM or Matrigel hydrogels. (Right) Representative images of actin cytoskeleton (green) and nucleus (blue) of endothelial cell sprouting
within FNPEG 0.5VPM and Matrigel hydrogels with 500 ng/mL VEGF supplemented in the media or no VEGF supplementation (scale bar: 150 μm). (Bottom left)
Quantification of sprouting by measuring the connected areas (mean ± SD, *p-value<0.05, **p-value< 0.01, ANOVA test with Tukey's post hoc test). (c) (Left)
Schematic of endothelial cell 3D reorganisation assay, in which HUVECs were encapsulated within VEGF-loaded or no-VEGF FNPEG 0.5VPM, Matrigel and PEG
0.5VPM only hydrogels. (Right) Representative z-axis projections of stacks at day 2 post-encapsulation (insets: representative slices of stack images at the same
magnification, actin cytoskeleton (green and nucleus (blue)), scale bar: 150 μm. (d) (left) Volume of objects (μm3) at days 1, 2 and 3 after encapsulation, as quantified
from stack images, and (right) representative 3D reconstructions of HUVECs within Matrigel, FNPEG 0.5VPM or PEG 0.5VPM at days 1, 2 and 3 (with VEGF)
(mean ± SD, n > 100 objects). FN hydrogels are cytocompatible and promote endothelial cell sprouting in 3D at levels comparable to Matrigel. (For interpretation
of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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and because this amount is different depending on the initial amount of
BMP2 loaded, we estimated that the FNPEG hydrogels contained 10.5
and 49.5 ng of BMP2 for initial loading of 5 and 75 μg/mL, respectively.
This means that the initial concentration of BMP2 in the hydrogels at
the time of implantation was 3.5 and 16.5 μg/mL, respectively. We note
that 10.5 and 49.5 ng of BMP2 in this bone model can be considered to
be ultralow and low doses [39,40].
An analysis of the bone defects implanted with FNPEG++ hydro-
gels, by micro computed tomography (μCT) scans, showed that the
defect was bridged in 2 out of 5 mice tested. When bone defects were
implanted with the FNPEG + hydrogels, varying results were recorded,
and no closure of the bone gap was observed (Fig. 5e–h). Likewise, the
bone gap remained unclosed in the FNPEG- control (Fig. 5e–h).
Quantification of bone volume (BV, mm3) showed that the highest in-
crease in bone formation occurred in the FNPEG++ implanted hy-
drogels, relative to the FNPEG- (no BMP2) controls (Fig. 5e). Some
FNPEG++-implanted bones also showed fusion to the ulna (Fig. 5f).
This could be due to the hydrogel swelling and coming into contact
with the ulna through the pores of the implant tube. Fusion to the ulna
for FNPEG++ in most cases resulted in bone forming also at the outer
part of the implant tube. Some bone growth was also observed coming
from the ulna in the FNPEG + condition. Although no bone-defect
closure was observed in the FNPEG + group, we observed a trend of
increased bone growth from FNPEG-, to FNPEG+ and to FNPEG++
that corresponded with increasing amounts of BMP2 in the implants
(Fig. 5e).
Longitudinal sections of the paraffin embedded forearms were
stained with safranin-O (that stains for cartilage, in red), fast green
(that stains for collagen) and haematoxylin (to counterstain the nuclei)
(Fig. 5g and h). Fig. 5g shows a whole mount of the implant tube po-
sition and greater collagen deposition (stained in blue) in the FNPEG+
and to FNPEG++ implanted bones, relative to the FNPEG- control,
which did not stain for collagen around the defect. Fig. 5h shows the
formation of new tissue within the implant tube in more detail. Cell
infiltration (as denoted by black arrows in Fig. 5h) was observed in the
FNPEG- hydrogels along the defect. The structures seen in this condi-
tion appear to resemble fat tissue. Some bone matrix deposits were
observed at the outer part of the implant, probably to mechanically
support the area. This is supported by the presence of osteoclasts at the
proximal end of the defect (Fig. S8), which would increase bone re-
sorption in that area (Fig. 5g).
In the FNPEG + condition, compact bone formation was observed
along the wall of the implant tube, with osteoblasts present at the outer
layer and bone resorption was also observed, as indicated by the pre-
sence of osteoclasts (Fig. 5h). This indicates that bone remodelling
occurred within the implant tube. Bone marrow cavities were also
present, which could indicate normal bone structure formation
(Fig. 5h).
In the FNPEG++ condition, implant tubes were filled with com-
pact bone, as well as with new bone and trabecular bone, which filled
the gap (Fig. 5g and h). The presence of newly formed bone, together
with that of bone marrow cavity structures, demonstrates that normal
Fig. 4. FN hydrogels promote capillary formation in vivo. (a) Representative images of chick chorioallantoic membrane (CAMs) (left column), green microscopy
channel used for quantification (middle column), and (right column) manually drawn images of capillary branching. Conditions tested from top to bottom: “empty”
(no hydrogel), “FNPEG VEGF” (FNPEG 0.5 VPM loaded with 125 ng VEGF), “FNPEG” (FNPEG 0.5 VPM), “PEG VEGF” (PEG only 0.5 VPM loaded with 125 ng VEGF)
and “PEG” (PEG only 0.5 VPM) (scale bar: 1 mm). (b) Schematic of the chick CAM assay, in which the egg shell is opened to expose the CAM and hydrogel samples
are carefully placed on top. (c) Number of branches per image (mean ± SD, n > 10 images) and (d) number of junctions per image (mean ± SD, n > 10 images).
FN hydrogels promote capillary formation in the chick chorioallantoic membrane assay.
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bone growth occurred within the implant tube. An endosteum-like
structure was observed next to the implant tube wall, which was sur-
rounded by osteoblasts, osteoclasts and compact bone. These results
suggest that low doses of BMP2 within these matrices can support
normal bone growth.
4. Discussion
We have developed a platform to engineer hydrogels that in-
corporate full-length FN within a synthetic polymer network and that
display controlled physico-chemical properties. FN has been extensively
used as a coating of surfaces and hydrogels in 2D mechanotransduction
studies [18,19]. The field is in need of biomaterials that replace
(caption on next page)
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Matrigel and can be used to engineer reproducible 3D environments
that support cellular complex processes, such as regeneration, devel-
opment and cancer studies. Fibrinogen is critically used in vivo as its
use is approved by the FDA for some applications (e.g. tissue sealant) as
opposed to Matrigel that is mostly used for in vitro applications. In this
regard, fibrinogen has been incorporated into a synthetic PEG hydrogel
that further improved classic fibrin gels as the biophysical properties
were fully defined because of the use of PEG as a backbone in which
fibrinogen was incorporated [41,75]. PEG-based hydrogels functiona-
lised with simple adhesive peptides (e.g. RGD) have also shown to
support complex biological structures such as intestinal organoids
[87,88]. Alternatively, a hyaluronic acid-based hydrogel has been de-
veloped as a platform for in vitro breast cancer culture [89]. These
systems have been successful in developing Matrigel alternatives.
However, using just PEG functionalised with adhesive peptides might
not recapitulate the full properties of the ECM and the HA-based hy-
drogels show limitations in controlling mechanical properties. Both of
them have limited affinity for growth factors, an essential aspect in the
successful performance of Matrigel. These limitations are overcome by
the use of FN-based hydrogels developed here.
To covalently incorporate FN into a PEG network, PEGylation of FN
has been reported in literature targeting either lysine residues [90] or
cysteine residues [91], resulting in biologically active FN. FN is dena-
tured during our PEGylation procedure (Fig. S2a). However, FN has the
capability of refolding after denaturation. Patel et al. characterised the
differences between native FN and refolded fibronectin (i.e. FN after a
denaturing-renaturing cycle) [92,93]. They found no differences in the
content of secondary structure, the affinity for gelatin or the capability
of FN to form fibrils. They also found evidence of higher affinity of
refolded FN for heparin. These findings suggest that FN's structure can
change during denaturation/PEGylation steps but still be able to
maintain several biological activities. The selection of cysteine residues
as target amino acid for the PEGylation step confers good selectivity as
cysteine residues are well characterised within the FN molecule. By
using thiol-PEGylation we are targeting specific regions on fibronectin
as all FNI and FNII domains contain two disulphide bonds, whereas
FNIII domains do not contain any [48]. This means the cell binding and
GF binding regions are not affected by PEGylation (Fig. S3).
FN was previously grafted into a hyaluronic acid hydrogel for 3D
cell culture [72]. To do this, they also PEGylated FN. They targeted
primary amines, which makes PEGylation unspecific, and added a 10-
fold molar excess of PEG for PEGylation. However, there was not en-
ough characterisation about the biological activities of FN after PEGy-
lation (e.g. availability of the integrin and GF binding domain). Criti-
cally, the FN hydrogels reported here allow the use of FN in controlled
3D environments and so can be used as controlled ECM mimetic to
extend mechanotransduction studies to 3D environments and develop
in vitro tissue models avoiding the use of uncontrolled matrices such as
Matrigel. These hydrogels are synthetic and tuneable, as shown by the
characterisation of its mechanical properties and degradation profiles
(Fig. 1 and Fig. S4). We demonstrate that full-length FN can be cova-
lently linked to these hydrogels without altering their key biological
activities. Our ELISAs (Figs. S3a–e) confirm that PEGylation occurred
mainly at the FNI and FNII domains (e.g. when using MAB1892 there is
a difference in antibody affinity comparing native and PEGylated FN,
while antibodies HFN7.1 and P5F3 that target FNIII domains show si-
milar affinity between native and PEGylated fibronectin). From our cell
adhesion studies (Fig. S3f-m) C2C12 cells are able to adhere and form
focal adhesions when seeded on top of PEGylated FN.
FN is a homodimer that presents a globular conformation in solution
(e.g. in plasma). FN in globular conformation contains some important
domains hidden such as the FNIII12-14 (i.e. the GF binding domain).
However, FN needs to change its conformation in order to expose those
cryptic domains that are unavailable in the globular conformation.
Therefore, FN fibrillogenesis, a cell-mediated process were FN is poly-
merised in 3D by cells, is essential to make these domains available
[94].
We demonstrate the efficacy of the system in two demanding ap-
plications, in 3D culture in vitro and in bone regeneration in vivo. We
show that FN hydrogels sequester VEGF from the environment and
promote vascularisation efficiently, both in vitro and in vivo. From our
release assays, we have observed differences in the capability of FNPEG
hydrogels to sequester VEGF and BMP2 (Fig. 2, Fig. S6 and Fig. 5a and
b). It has been previously shown that BMP2 has higher affinity to FN
compared to VEGF, which is contrary to what our release studies sug-
gest as VEGF is retained more in the hydrogels [15]. This could be
explained because of the different molecular weight (BMP2 has lower
molecular weight than VEGF). This could factor in a quicker release of
BMP2 since there is a burst release during the first hours. This is in
accordance with our data obtained from release experiments of BMP2
with different concentrations of BMP2 (Fig. 5a and b). Additionally,
another VEGF binding site on FN has been identified [95]. Mitsi et al.
found two types of VEGF-FN binding, one constitutively available and
another controlled by changes in conformation of FN. They also showed
that hydrophilic substrates increased a more extended conformation of
FN, which they found to enhance VEGF binding. This could explain the
differences seen in our release experiments for VEGF and BMP2. PE-
Gylated VEGF was used as a strategy to deliver VEGF upon protease
cleavage in PEG-based hydrogels [82]. In this case VEGF delivered from
PEG-RGD performed poorly compared to VEGF-free GFOGER-PEG hy-
drogels for vascularisation in a bone defect in vivo. Taking into account
the poor performance of PEG-RGD in literature studying similar hy-
drogels (4- arm-PEG-maleimide using Michael-type addition reaction)
[82] and our data showing a quick release of VEGF from PEG-RGD
hydrogels (Fig. S6), we did not include PEG-RGD in our studies.
FN hydrogels loaded with low concentrations of BMP2 can also
promote bone growth in a non-healing mouse bone defect model. Note
here that Matrigel was not selected as a control condition due to its lack
of potential translatability. Few studies use Matrigel with bone mor-
phogenetic proteins, for example Langenfeld et al. used Matrigel to-
gether with BMP2 to assess the promotion of angiogenesis in tumours
[96]. In this regard, fibrinogen-based hydrogels [63], which was one of
the first attempts to engineer protein-based synthetic hydrogels seeking
to recapitulate features of the ECM, have been used to load BMP2 for
bone regeneration. This was used to achieve regenerative effect in an
athymic nude mice (immunodeficient) cranial defect model [41].
Fig. 5. FN hydrogels promote bone growth in vivo. (a) Cumulative release of fluorescently labelled BMP2 from FNPEG 0VPM hydrogels and PEG 0VPM only
hydrogels (%, mean ± SD, n = 4). (b) Percentage release of fluorescently labelled BMP2 at 24 h when loading 5 and 75 μg/mL of BMP2 in FNPEG 0.5VPM
hydrogels. (c) Picture of an implant tube to be filled with hydrogels. (d) Scheme of the critical-size defect model, where the radius is segmentally cut creating a
2.5 mm defect but leaving the ulna intact. (e) The percentage of bone volume (BV) quantified in FNPEG- (no BMP2, control FNPEG 0.5VPM), and in FNPEG+ and
FNPEG++ hydrogels (FNPEG 0.5VPM), which were initially loaded with 10.5 and 49.5 ng of BMP2, respectively (mean ± SD, n = 5, *p-value 0.0086). (f) 3D
reconstructions of micro computed tomography (μCT) scans showing 4 mm of the ulna (left) and the radius (right), where the implant tube was placed. (g) Whole
mount, longitudinal sections of representative forearms, with the proximal end to the left (scale bar: 1 mm). Yellow colour shows the walls of the implant tube. (h)
Representative histological images of bone repair in each treatment group and the FNPEG- control (showing safranin O, fast green and haematoxylin staining) (scale
bar: 100 μm). Black arrows show cell infiltration, * indicates bone deposition, ** marks fibrotic tissue, NB shows new bone formation, CB shows compact bone, OBs
are osteoblasts indicated by white arrows, OCs are osteoclasts indicated by white arrowheads, TB shows trabecular bone, and BM shows bone marrow cavities. These
results show that FN hydrogels promote bone growth at low BMP2 concentrations. (For interpretation of the references to color in this figure legend, the reader is
referred to the Web version of this article.)
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However, FN offers synergy between integrin and GF receptors [25,40]
which allows ultralow doses of GFs to be used (e.g. we used 10.5 ng and
49.5 ng of BMP2 per implant to achieve regenerative effects in a murine
(wild type) non-healing radial defect model). To contextualise the
amounts of BMP2 used in our in vivo study, Shekaran and colleagues
used similar hydrogels (4-arm-PEG-maleimide based hydrogels) loaded
with BMP2 and used the same murine radial bone defect model [86].
They first compared the performance for osteogenesis in vitro of these
PEG hydrogels combined with either the GFOGER peptide or RGD
peptide (even at 2 mM concentration) and they observed that GFOGER-
PEG hydrogels promoted greater osteogenesis than PEG-RGD. For the
critical size defect model they loaded 20, 40 and 200 μg/mL of BMP2
into the GFOGER-PEG hydrogels, considering 20 μg/mL low dose of
BMP2.
Similarly, Cheng et al. used a murine femoral critical size defect
model to study the delivery of BMP2 and testosterone in bone re-
generation [97]. They used a polypropylene fumarate (PPF)/tricalcium
phosphate (TCP) scaffold to load either BMP2, BMP2 and testosterone
or testosterone alone. In this case, they reported that the best condition
had both BMP2 and testosterone (5 and 10 μg, respectively). Another
example of co-delivery of BMP2 was reported by Zwingenberger et al.,
where they used a murine femoral critical size defect model [98]. Here,
they considered 2.5 μg a low dose of BMP2, which was loaded into a
heparinized mineralized collagen type I matrix. They observed greater
bone formation when co-delivering BMP2 and stroma cell-derived
factor-1 (SDF-1α) (2.5 and 10 μg, respectively). Ben-David et al., used
PEG-fibrinogen loaded with low dose of BMP-2 in a critical size cal-
varial defect model (5 mm diameter defect, 1.5 mm thick, 1 μg of
BMP2, 8 μg/mL) [41].
It remains for future studies to address whether bone regeneration
could be improved by further optimising the initial amount of BMP2
loaded into the implant tube, and whether the generation of stiffer
hydrogels could promote osteogenesis by the stem cells available at the
fracture site. We note that the presence of FN in our hydrogels provide
cell attachment, as it would happen in a PEG-RGD hydrogel. However,
in growth factor release experiments comparing PEG, PEG-RGD and
FNPEG (Fig. S6), we obtained that PEG-RGD had a similar release to
PEG only, which suggests that the amount of GF in the hydrogel would
be too low to play a significant biological role. This hypothesis is in line
with results published on PEG-RGD hydrogels, where they found poor
osteogenesis from PEG-RGD hydrogels that led the authors to in-
vestigate PEG-GFOGER hydrogels instead [86].
5. Conclusion
Overall, our findings demonstrate that GFs can be efficiently pre-
sented in a highly controllable, fully synthetic, 3D microenvironment
for use in multiple tissue-engineering applications. The FN hydrogel
system has the potential to substitute Matrigel in 3D culture models,
given that it is a chemically defined system that contains full-length
proteins and distinct, solid-phase, presentation of GFs. This system can
also be produced using purified human recombinant proteins, removing
the need to screen for pathogens as occurs when using Matrigel ma-
trices. The chemistries used to form the hydrogels are mild, cyto-
compatible and spontaneous at physiological pH and temperature.
Moreover, the FN-based hydrogels are transparent, and so are well-
suited for colorimetric/fluorometric assays. Being a biosynthetic
system, it has the potential to be more amenable for translation in e.g.
drug testing platforms or tissue engineering [87].
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